The results showed that the PRR34‐AS1 methylation level may be a potential marker for distinguishing AML (especially non‐APL‐AML) patients from normal controls (95% CI = 0.513–0.722, p = 0.060, AUC = 0.617; 95% CI = 0.529–0.749, p = 0.032, AUC = 0.639; Figure 3A,B). This evidence concerns the gene PRR34 and acute promyelocytic leukemia.